HARROW, INC. (HROW): Entry into a Material Definitive Agreement
HARROW, INC. (HROW) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Harrow Acquires Global Rights to TYRVAYA ® , the First and Only FDA-Approved Nasal Spray for Dry Eye Disease NASHVILLE, Tenn., August 6, 2026 – Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that
How this was made
The 30-second read
Why it matters
The filing provides deal structure (cash at closing plus milestone payments), asset scope (NDA, IP, inventory, contracts), and key execution risks (closing conditions, potential non-completion).
Market read
Traders can update deal-driven expectations for Harrow’s future cash flows and risk, with the main uncertainty centered on closing timing and milestone attainment.
What to watch
Closing is subject to customary conditions and timing is uncertain; any delays or required regulatory/contractual steps could defer value realization and increase execution risk.
Background
Harrow (HROW) filed an 8-K describing an Asset Purchase Agreement with Viatris to acquire global rights to TYRVAYA nasal spray for dry eye disease.
Ticker impact
Harrow entered an asset purchase agreement to acquire global rights to TYRVAYA, paying $30M cash plus up to $70M in milestones.
Likely positive re-rating on deal announcement, with follow-through dependent on deal closing progress and milestone outlook.
The 8-K discloses concrete consideration ($30M cash, up to $70M contingent) and the asset scope (NDA, IP, inventory, contracts), which can materially affect expectations for Harrow’s future revenue and risk profile.
Market effects
Signals continued consolidation in ophthalmology/respiratory specialty pharma around established branded assets and milestone-based economics.
Primarily US-listed pharma sentiment; limited direct regional spillover beyond specialty pharma investors.
Global rights acquisition suggests cross-border commercialization and regulatory transfer considerations, but no additional jurisdictions are specified.
Counterpoint
The $70M is contingent on net sales thresholds, so the headline economics may overstate near-term earnings impact if TYRVAYA sales underperform.
Key entities
- public_companyHarrow, Inc.
US-listed acquirer entering an asset purchase agreement for TYRVAYA global rights.
- public_companyViatris Inc.
Seller providing TYRVAYA assets and related regulatory/IP materials to Harrow.
- product_assetTYRVAYA (varenicline solution) nasal spray 0.03 mg
Cholinergic agonist indicated for dry eye disease; acquisition includes NDA and approvals.
